PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates
First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD")   Restructuring of Sanofi and Oxford Agreements   Receipt of $5 Million Milestone and Material Payments from Sanofi and Proceeds Used to Repay Debt
View HTML
Toggle Summary Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi
Regulus to Receive Remaining $5 Million Payment for Enrollment Milestone LA JOLLA, Calif. , Nov. 2, 2020 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that
View HTML
Toggle Summary Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
LA JOLLA, Calif. , Oct. 15, 2020 /PRNewswire/ -- Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced initiation of dosing in its Phase 1b clinical
View HTML
Toggle Summary Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi
Proceeds Used to Repay Debt Principal with Oxford Finance LA JOLLA, Calif. , Oct. 13, 2020 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS) (the "Company" or "Regulus"), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today
View HTML
Toggle Summary Regulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference
LA JOLLA, Calif. , Sept. 11, 2020 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of
View HTML
Toggle Summary Regulus Therapeutics to Present at the 2020 Wells Fargo Virtual Healthcare Conference
LA JOLLA, Calif. , Sept. 3, 2020 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of
View HTML
Toggle Summary Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements
LA JOLLA, Calif. , Aug. 31, 2020 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that pursuant to an amendment of its term loan agreement with Oxford LLC ,
View HTML
Toggle Summary Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent Updates
Completion of Dosing in Phase 1 Multiple Ascending Dose Study ("MAD") of RGLS4326 in Healthy Volunteers for Autosomal Dominant Polycystic Kidney Disease ("ADPKD")   FDA Orphan Designation of RGLS4326 for ADPKD   Appointment of Denis Drygin, Ph.D., as Chief Scientific Officer LA JOLLA, Calif. , Aug.
View HTML
Toggle Summary Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
LA JOLLA, Calif. , Aug. 6, 2020 /PRNewswire/ -- Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of
View HTML
Toggle Summary Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer
LA JOLLA, Calif. , Aug. 3, 2020 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Denis Drygin , Ph.D., as
View HTML